drugset / Trial / NCT05198817
A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients
NaSingle-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-2002 injection monotherapy and in combination with other anti-cancer therapy for advanced malignant tumors of patients. To explore the reasonable dosage of SHR-2002 injection monotherapy and dosage regimen of combination therapy for advanced malignant tumors of patients.
Timeline
- Start
- 2022-02-22
- Primary completion
- 2023-01-31
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | — |
| Subject | SHR-2002 | Unknown | — | — |